(agglutination)
45,694 results
  • Idiopathic multicentric Castleman disease in an HIV-positive child. [Case Reports]
    BMJ Case Rep. 2026 Oct 07; 19(10).Pretorius N, van Marle AC, … Haupt LBC
  • A preadolescent HIV-positive girl from Southern Africa presented to a public healthcare facility with fever and unilateral facial and neck swelling. Clinical examination revealed generalised lymphadenopathy, hepatosplenomegaly, hypertension and haematuria. A provisional diagnosis of poststreptococcal glomerulonephritis was made; however, when the patient displayed no clinical improvement on suppo…
  • Brucella prosthetic joint infection following total knee arthroplasty: a rare case report. [Case Reports]
    Front Surg. 2026; 13:1853630.Almohideb F, Alkhateeb A, … Alfaqih AFS
  • CONCLUSIONS: Brucella PJI should be considered in painful arthroplasties in endemic settings. Successful management requires a high index of suspicion, appropriate microbiological diagnosis, prolonged combination antimicrobial therapy, and individualized surgical intervention based on implant stability. Persistence of Brucella in intraoperative cultures despite three months of appropriate systemic therapy, as seen here, argues that implant retention is inadequate once components are radiographically loose.
  • A distinctive RhD serologic phenotype expressed by p.Glu233Lys RHD alleles DV type 5 and DAU4 in microplate agglutination RhD typing. [Journal Article]
    Transfusion. 2026 Oct 02. [Online ahead of print]Karne V, Jedrzejczak MJ, … Hudgins JPT
  • CONCLUSIONS: DV.5 and DAU4 alleles express disruptive p.Glu233Lys and are associated with hemolytic anti-D. Microplate RhD typing with decreased IgM anti-D4 reactions did not associate DV.5 and DAU4 with alloimmunization but indicated increased risk of anti-D alloimmunization. Similar epD6.1-weak, epD6.4-strong RhD reactions were observed in 10 DV.5 patients using automated microcolumn typing. Development of anti-D reagents detecting patients with other partial RHD genotypes beyond DVI is desirable.
  • Complement inhibition by sutimlimab in cold agglutinin disease promotes red blood cell agglutination and may lead to circulatory complications, eryptosis and hemolysis. [Case Reports]
    Front Immunol. 2026; 17:1906515.Bartolmäs T, Mayer B, Salama AFI
  • CONCLUSIONS: The observed increase in RBC agglutination under sutimlimab treatment is likely due to a substantial reduction of C3d deposition on RBCs. This mechanism also represents the most plausible explanation for the side effects observed in some patients with CAD receiving the drug, such as aggravation of circulatory complications, including acrocyanosis, Raynaud's phenomenon, and less commonly, organ dysfunction. Inhibition of early complement components (C1-C3) may therefore not only prevent hemolysis in CAD but paradoxically also promote RBC agglutination, eryptosis, and hemolysis in certain cases. Pre-treatment serological testing with sutimlimab may help predict some of these adverse effects.